Please login to the form below

Not currently logged in
Email:
Password:

US supreme court considers Reglan appeal

Should generics firms be held accountable for failing to flag up drug side effects, the US Supreme Court asks

The US Supreme Court has asked the Obama Administration for its opinion about whether generic drug makers should be held accountable for failing to adequately warn about the side effects associated with their drugs. The request comes as the Justices consider whether or not they should hear an appeal made by generic drug makers such as Teva Pharmaceuticals, Actavis Elizabeth and UDL Laboratories in a tardive dyskinesia lawsuit over generic Reglan (metoclopramide).

The drug makers have been accused of failing to adequately warn about the risk of movement problems, such as tardive dyskinesia, as side effects of Reglan. Actavis, and the other generic drug makers, however argue that the claims should be pre-empted by federal laws governing generic drug labelling, which require generic drugs to carry the same label as the brand name medication.

In an order issued this week, the Supreme Court has invited the Solicitor General to file briefs in the cases expressing the views of the United States.

At issue on appeal is whether a generic drug manufacturer can change its label or otherwise warn the public of a health risk before the maker of the brand name drug. FDA regulations require that generics seeking approval have the same label as the brand name manufacturer, and it also stipulates that the generic's label has to remain consistent with the brand name label.

However, the lower appeals court ruled that the regulations do not prevent generics from requesting a label change to warn of a health risk, nor do they prevent the drug company from other methods of warning the public, such as sending out a "Dear Healthcare Professionals" letter to warn of potential risks.

In February 2009, the FDA required that manufacturers of all variations of generic metoclopramide add a black box warning about the Reglan tardive dyskinesia risk, which is the strongest warning that can be placed on a prescription medication. The generic drug makers were also required to develop mitigation and risk evaluation strategies to ensure patients are aware of the potential side effects.

2nd June 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics